Linked Life Data

21160730

Source:http://linkedlifedata.com/resource/pubmed/id/21160730

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2010-12-16
pubmed:abstractText
Clopidogrel is a mainstay in the treatment of patients with acute coronary syndromes or those receiving endovascular prostheses. However, its efficacy has been challenged in the recent past by studies suggesting variable individual responsiveness and by new, more potent competitors, such as prasugrel and ticagrelor. But what is the actual body of evidence in support of clopidogrel? Is there any dark side of the moon? What is the role of prasugrel, which has already been approved in Europe and in the United States? And what will be the future role of ticagrelor, when approved for routine clinical practice? We hereby concisely summarize the scope of this clinical choice, providing arguments in favor and against each of the three antiplatelet agents: clopidogrel, prasugrel, and ticagrelor.
pubmed:language
eng
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:month
Jun
pubmed:issn
1949-8462
pubmed:author
pubmed:issnType
Electronic
pubmed:day
26
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
131-4
pubmed:year
2010
pubmed:articleTitle
Alternatives to clopidogrel for acute coronary syndromes: Prasugrel or ticagrelor?
pubmed:affiliation
Giuseppe Biondi-Zoccai, Marzia Lotrionte, Fiorenzo Gaita, Division of Cardiology, University of Turin, San Giovanni Battista "Molinette" Hospital, 10126 Turin, Italy; Unit for Heart Failure and Cardiac Rehabilitation, Catholic University, 00136 Rome, Italy.
pubmed:publicationType
Journal Article